Research Seminars

About

Research Seminars gather a small number (20 to 100) of well-established and preferably young investigators to address scientific topics in depth and help break new ground. Research Seminars take place over two days in easy-to-reach European cities. They are scientific Seminars involving recently published work and research in progress. Participation is fully supported by the budget granted by the ERS.



Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD

Despite remarkable progresses in the definition of cellular, biochemical and molecular biology pathways in the pathogenesis of Severe Asthma, Chronic Obstructive Pulmonary Disorder (COPD) and Interstitial Lung Disorders (ILDs), there is still a substantial unmet need for new drugs able to control and/or change the natural history of these diseases. This Seminar intended to underline the key role of a side-to-side collaboration between clinicians, scientists, bioinformaticians and statisticians in the comprehension of pathological processes underlying different respiratory disorders. It provided a framework to improve the ability to identify potential pharmacological targets for the development of innovative drugs.
Characterisation of clinical phenotypes is mandatory for the development of new drugs
N. Roche (Paris, France)
Slide presentation
Slide presentation
Asthma and COPD: similarities and differences in pathogenesis
A. Di Stefano (Veruno, Italy)
PDF journal article, handout or slidesSlide presentation
PDF journal article, handout or slidesSlide presentation
Bioinformatic tools for systems medicine in allergy
M. Benson (Linköping, Sweden)
PDF journal article, handout or slidesSlide presentation
PDF journal article, handout or slidesSlide presentation
Human translational medicine – phenotyping is key
R. Djukanovic (Southampton, United Kingdom)
PDF journal article, handout or slides
PDF journal article, handout or slides
Lipidomic phenotyping of severe asthma
J. Brandsma (Southampton, United Kingdom)
Slide presentation
Slide presentation
New drugs for severe asthma – what should we target and how?
K.F. Chung (London, United Kingdom)
PDF journal article, handout or slidesSlide presentation
PDF journal article, handout or slidesSlide presentation
Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation
L. Uller (Lund, Sweden)
PDF journal article, handout or slidesSlide presentation
PDF journal article, handout or slidesSlide presentation
Developing integrated handprints of severe asthma: the U-BIOPRED approach
B. De Meulder (Lyon, France)
Slide presentation
Slide presentation
Human translational medicine in ILD: the promise of new drugs
O. Eickelberg (Munich, Germany)
PDF journal article, handout or slides
PDF journal article, handout or slides
Multivariate analysis in a megavariate world: applications of multivariate modeling to biomarker identification in pulmonary medicine
C. Wheelock (Stockholm, Sweden)
No content made available
No content made available
New Drugs for COPD: the current status
I. Adcock (London, United Kingdom)
PDF journal article, handout or slidesSlide presentation
PDF journal article, handout or slidesSlide presentation
COPD – will new insights into molecular pathology define new therapies?
C. Greene (Dublin, Ireland)
PDF journal article, handout or slidesSlide presentation
PDF journal article, handout or slidesSlide presentation
What are the knowledge gaps in COPD that prevent new drug development?
G. Caramori (Ferrara, Italy)
PDF journal article, handout or slidesPDF journal article, handout or slides
PDF journal article, handout or slidesPDF journal article, handout or slides
Chaperonins in COPD
F. Cappello (Palermo, Italy)
Slide presentation
Slide presentation